US 12,123,021 B2
Gene-regulating compositions and methods for improved immunotherapy
Micah Benson, Cambridge, MA (US); Jason J. Merkin, Cambridge, MA (US); Gregory V. Kryukov, Cambridge, MA (US); Solomon Martin Shenker, Cambridge, MA (US); Michael R. Schlabach, Cambridge, MA (US); Noah Jacob Tubo, Cambridge, MA (US); and James Martin Kaberna, II, Cambridge, MA (US)
Assigned to KSQ Therapeutics, Inc., Lexington, MA (US)
Filed by KSQ Therapeutics, Inc., Cambridge, MA (US)
Filed on Mar. 29, 2022, as Appl. No. 17/707,725.
Application 17/707,725 is a continuation of application No. 16/951,310, filed on Nov. 18, 2020, granted, now 11,332,713.
Application 16/951,310 is a continuation of application No. 16/354,100, filed on Mar. 14, 2019, granted, now 11,261,428.
Claims priority of provisional application 62/804,261, filed on Feb. 12, 2019.
Claims priority of provisional application 62/790,179, filed on Jan. 9, 2019.
Claims priority of provisional application 62/790,192, filed on Jan. 9, 2019.
Claims priority of provisional application 62/768,441, filed on Nov. 16, 2018.
Claims priority of provisional application 62/768,428, filed on Nov. 16, 2018.
Claims priority of provisional application 62/736,185, filed on Sep. 25, 2018.
Claims priority of provisional application 62/692,016, filed on Jun. 29, 2018.
Claims priority of provisional application 62/692,010, filed on Jun. 29, 2018.
Claims priority of provisional application 62/643,584, filed on Mar. 15, 2018.
Claims priority of provisional application 62/643,578, filed on Mar. 15, 2018.
Prior Publication US 2022/0220442 A1, Jul. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); A61P 35/04 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01); C12N 15/113 (2010.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); A61P 35/04 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 16/2803 (2013.01); C07K 16/2863 (2013.01); C07K 16/32 (2013.01); C12N 9/22 (2013.01); C12N 15/11 (2013.01); C12N 15/113 (2013.01); C12N 15/1135 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2319/30 (2013.01); C12N 2310/122 (2013.01); C12N 2310/14 (2013.01); C12N 2310/20 (2017.05); C12N 2310/531 (2013.01); C12N 2800/80 (2013.01)] 12 Claims
 
1. A modified human tumor-infiltrating lymphocyte (TIL) comprising an insertion, a deletion, or a mutation in an endogenous SOCS1 gene, wherein endogenous SOCS1 gene expression and/or function is reduced in the modified human TIL, relative to endogenous SOCS1 gene expression and/or function in an unmodified human TIL, and wherein anti-tumor efficacy of the modified human TIL is increased, relative to anti-tumor efficacy of an unmodified human TIL.
 
11. A method of producing a modified human TIL, comprising introducing a gene-regulating system into a human TIL and culturing the human TIL to produce the modified human TIL of claim 1.